Sangamo Therapeutics 株価情報 (NASDAQ: SGMO)

最新ニュース Sangamo Therapeutics (NASDAQ:SGMO) 株価情報

SANGAMO THERAPEUTICS INC

Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 80.6% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $9.6 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares rose 25.15% to $1.84. The market value of their outstanding shares is at $1.2 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock moved upwards by 23.77% to $0.54. The market value of their outstanding shares is at $2.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares moved upwards by 23.73% to $0.77. The market value of their outstanding shares is at $173.0 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 14.89% to $1.08. The company's market cap stands at $14.7 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 12.06% to $0.68. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) shares declined by 57.2% to $1.01 during Friday's pre-market session. The company's market cap stands at $46.4 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock fell 41.28% to $0.51. The market value of their outstanding shares is at $15.5 million. </li>
<li>XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shares decreased by 35.09% to $16.71. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 30.39% to $1.26. The market value of their outstanding shares is at $16.7 million. </li>
<li>Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) shares decreased by 23.34% to $13.01. The company's market cap stands at $417.9 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock fell 22.75% to $7.2. The market value of their outstanding shares is at $315.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDRX

DNTH

ENTO

KAPA

KRMD

MAZE

NMTC

SGMO

XOMAP

ZVSA

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stock futures declined on Friday after a bloodbath on Thursday following the introduction of President Donald Trump&#8216;s tariffs. Futures of major benchmark indices were lower in premarket trading.
Fueled by a broad market downturn, the Dow Jones plummeted by a staggering 1,679 points, its fifth-largest drop ever, while the S&amp;P 500 and Nasdaq suffered their biggest single-day losses since June and March 2020, respectively.
Trump, however, dismissed the tariff-induced selloff and said, &#8220;The market is going to boom, the stock is going to boom, the country is going to boom.&#8221;
The 10-year Treasury bond yielded 3.94% and the two-year bond was at 3.61%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in a 69.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.00%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.42%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 0.71% to $532.87, while the QQQ declined 0.62% to $447.85, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Technology sectors bore the brunt of Thursday&#8217;s U.S. stock market downturn. Specifically, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares plummeted approximately 9.3%, marking their steepest single-day decline since March 2020. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also saw a significant drop, tumbling 7.8%, while Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell by 8.98%. Across the broader market, consumer discretionary, energy, and information technology stocks registered the most substantial losses within the S&amp;P 500.
In contrast, consumer staples stocks stood out, bucking the prevailing negative trend and closing the session higher. This sector&#8217;s resilience was highlighted by Lamb Weston Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>), whose shares surged 10% after the company released third-quarter financial results that exceeded expectations and provided FY25 sales guidance above analyst estimates.
Economic data released Thursday presented a mixed picture. U.S. initial jobless claims decreased by 6,000 to 219,000 for the week ending March 29, falling below the anticipated 225,000. Additionally, the U.S. trade deficit narrowed to $122.7 billion in February, improving from $130.7 billion in January and slightly better than the forecasted $123.5 billion. However, the ISM services PMI declined to 50.8 in March, down from 53.5 in February and below market expectations of 53.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-5.97%</td>
<td>16,550.60</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-4.84%</td>
<td>5,396.52</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-3.98%</td>
<td>40,545.93</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-6.59%</td>
<td>1,910.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
CNBC&#8217;s Jim Cramer compared Trump&#8217;s tariffs to historical tariff regimes in the U.S., in an X post. he said, &#8220;It is not pro-tariff v. anti-tariff. It&#8217;s about accomplishing what&#8217;s good for our country while not having a Smoot-Hawley situation.&#8221;
The Smoot-Hawley Tariff Act, enacted in 1930, was a US law that significantly increased tariffs on imported goods, intended to protect American businesses and farmers, but ultimately worsened the Great Depression by triggering a global trade war.
However, he added that tariff-induced selloff on Thursday was &#8220;100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It is not pro-tariff v. anti-tariff. It&#39;s about accomplishing what&#39;s good for our country while not having a Smoot Hawley situation. Yesterday was 100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1908066366805991875?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
AQR Capital Management&#8217;s Chief Investment Officer, Cliff Asness, took to X on Thursday to voice his criticism of tariff proponents, specifically disputing the assertion that tariffs result in deflation instead of inflation.
His remarks were a direct response to Anthony Pompliano, the Founder &amp; CEO of Professional Capital Management and a well-known Bitcoin advocate, who had previously claimed, &#8220;Tariffs don't create inflation. The exact opposite happens."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Idiots say this and bray like they've scored a great point. What they mean is giant arbitrary tariffs are so bad they eventually cause recessions which then cause deflation. They then present this as a feature. And if they don't mean that they are even more wrong in some… <a href="https://t.co/ZihK0rbRU0">https://t.co/ZihK0rbRU0</a>
&mdash; Clifford Asness (@CliffordAsness) <a href="https://twitter.com/CliffordAsness/status/1907915579324760564?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Creative Planning&#8217;s chief market strategist, Charlie Bilello, noted that the VIX index reached its highest closing level since Aug. 5, 2024.
He suggested this increase in fear, coupled with lower stock prices, presents enhanced opportunities for investors with a long-term perspective. Bilello also pointed to historical trends, indicating that the S&amp;P 500 has historically delivered &#8220;higher than average&#8221; returns following significant surges in volatility.
He shared data showing that after a comparable spike on Aug. 5, 2024, the S&amp;P 500 returned 6% in one month, 11% in three months, and 18% over six months. On average, Bilello highlighted, the S&amp;P 500 has gained 12% six months after such volatility spikes and 21% after a year.
In an X post, Bilello summarized, &#8220;More Fear = More Opportunity.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24VIX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VIX</a> spiked nearly 40% higher today and closed above 30 for the first time since last August. What has happened in the past following the biggest volatility spikes? Higher than average forward S&amp;P 500 returns. More Fear = More Opportunity<a href="https://t.co/wMMGtwYloS">https://t.co/wMMGtwYloS</a> <a href="https://t.co/vVEN5vUBD1">pic.twitter.com/vVEN5vUBD1</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1907910013743722855?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>March&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Fed Chairman Jerome Powell will speak at 11:25 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Michael Barr will speak at 12:00 p.m. and Fed Governor Christopher Waller will speak at 12:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) was up 0.34% in premarket on Friday ahead of its earnings before the opening bell. Analysts expect a quarterly earnings of 1 cent per share on revenue of $7.70 million.</li>
</ul>
<ul>
<li>Neuroone Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) slumped 36.05% after the company disclosed a common stock public offering.</li>
</ul>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was up 2.50% after posting stronger-than-expected results for its second quarter and issuing an upbeat FY25 earnings forecast.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) surged 32.41% after announcing a new agreement with pharmaceutical giant Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.</li>
</ul>
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) jumped 3.98% after its CEO, Ryan Cohen, acquired 500,000 shares of the company.</li>
</ul>
<ul>
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) dropped 26.96% after the company said that it will enact a 1-for-10 reverse stock split effective Monday to meet Nasdaq&#8217;s bid price requirements.</li>
</ul>
<ul>
<li>Mullen Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) zoomed 83.64% after it stated that its U.S.-assembled Mullen and Bollinger commercial EV inventory is tariff-exempt.</li>
</ul>
<ul>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) gained 40.06% after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.57% to hover around $64.56 per barrel.
Gold Spot US Dollar declined 0.97% to hover around $3,083.92 per ounce. Its fresh record high stood at $3,168.04 per ounce. The U.S. Dollar Index spot was higher by 0.48% at the 102.564 level.
Asian markets closed on a lower note on Friday. India's S&amp;P BSE Sensex, Japan's Nikkei 225, Australia's ASX 200, China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi index fell. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44642317/sp-500-plummets-108-nasdaq-100-corrects-141-since-trumps-inauguration-heres-how-it-compares-to-obama-and-biden-eras">S&amp;P 500 Plummets 10.8%, Nasdaq 100 Corrects 14.1% Since Trump&#8217;s Inauguration: Here&#8217;s How It Compares To Obama And Biden Eras</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

Government

Market Summary

News

Futures

Commodities

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

AAPL

AMZN

BGLC

CXAI

MULN

NVDA

Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) <a href="https://www.benzinga.com/quote/sgmo">capsid, STAC-BBB.</a>
Sangamo Therapeutics shares jumped 39.5% to $0.8684 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) gained 115.3% to $0.9990 in pre-market trading after falling around 19% on Thursday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) rose 82% to $0.1447 in pre-market trading after dipping over 22% on Thursday.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 69.4% to $0.3303 in pre-market trading after jumping 23% on Thursday.</li>
<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) rose 49.3% to $5.00 in pre-market trading.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 40.1% to $0.6123 in pre-market after gaining 6% on Thursday.</li>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) surged 37.6% to $1.11 in pre-market trading after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
<li>Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) gained 20% to $7.09 in pre-market trading following a 5% decline on Thursday.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) gained 11.1% to $7.90 in pre-market trading after falling 6% on Thursday.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) rose 4.5% to $9.61 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Lesaka Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSAK#NASDAQ">LSAK</a>) fell 57.8% to $2.00 in pre-market trading.</li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) shares fell 48.7% to $6.31 in pre-market trading following a 5% decline on Thursday.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 38.3% to $2.01 in pre-market trading.</li>
<li>Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) fell 22.6% to $4.21 in pre-market trading after dipping 9% on Thursday.</li>
<li>MeridianLink, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) dipped 20.5% to $13.99 in pre-market trading after falling 4% on Thursday.</li>
<li>Insteel Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) shares tumbled 18.3% to $20.11 in pre-market trading. Insteel Industries will announce its second quarter 2025 earnings on Thursday, April 17.</li>
<li>Global Industrial Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) fell 17.3% to $18.00 in today's pre-market trading after dipping 5% in Thursday.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) fell 16.7% to $6.16 in pre-market trading after dipping 7% on Thursday.</li>
<li>Heritage Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) shares dipped 16.1% to $13.11 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) shares fell 15.7% to $3.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Trading Ideas

ADPT

HRTG

IIIN

LION

LSAK

MLNK

OLMA

RNAC

SHCO

SLSR

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) to report quarterly earnings at 1 cent per share on revenue of $7.70 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Shared Hospital Services shares rose 0.3% to $2.97 in after-hours trading.</li>
<li>Guess? Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) reported upbeat results for its fourth quarter and named Alberto Toni as CFO. The company said it sees FY26 revenue to increase 3.9% &#8211; 6.2% in US Dollars and adjusted EPS of $1.32 &#8211; $1.76. Guess shares fell 2.4% to $9.80 in the after-hours trading session.</li>
<li>NeuroOne Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) disclosed a common stock public offering. NeuroOne Medical shares dipped 36.1% to $0.5499 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) posted stronger-than-expected results for its second quarter and issued upbeat FY25 earnings forecast. Simulations Plus shares gained 2.5% to $24.41 in the after-hours trading session.</li>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB. Sangamo Therapeutics shares jumped 47.7% to $0.9193 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Editor&#8217;s Note: The story has been updated to include the correct price action for Tesla stock.
The stock market experienced a <a href="https://in.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">significant downturn</a> today, with the&nbsp;S&amp;P 500&nbsp;dropping nearly 5% to 5,396.52, marking its worst session since September 2022. The&nbsp;Nasdaq&nbsp;also faced a steep decline of nearly 6% as fears of retaliatory actions from U.S. trading partners spread across markets. The tech-heavy index ended the day at 16,550.61. The Dow Jones Industrial Average dropped almost 4% to 40,545.93.
These are the top stocks that gained the attention of retail traders and investors throughout the day.
RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>)
RH&#8217;s stock plummeted 40.09% to close at $149.39, hitting an intraday high of $166.09 and a low of $138.40. The stock&#8217;s 52-week high and low stand at $457.26 and $138.40, respectively. The shares gained 1.9% in after-hours trading. The sharp decline followed the company&#8217;s&nbsp;<a href="https://www.benzinga.com/25/04/44626074/rh-posts-downbeat-earnings-joins-apple-tesla-nvidia-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session">disappointing earnings report</a>&nbsp;for the fourth quarter, which fell short of expectations, contributing to the pre-market losses. Revenue for the period came in at $812.41 million, which missed the consensus estimate of $829.56 million.
Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)
Five Below saw its shares fall 27.81%, closing at $58.83. The stock reached an intraday high of $65.37 and a low of $56.90, with a 52-week range of $166.55 to $56.90. The retail sector, including Five Below, was heavily impacted by&nbsp;President Donald Trump&#8217;s tariff plan, which <a href="https://in.benzinga.com/news/global/25/04/44632479/retail-stocks-slammed-as-trumps-tariff-plan-sends-shockwaves-through-sector">sent shockwaves</a> through the market, leading to a sell-off.
Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>)
Sangamo Therapeutics&#8217; stock declined 4.73% to $0.62, with an intraday high of $0.64 and a low of $0.58. The stock&#8217;s 52-week high and low are $3.18 and $0.30, respectively. Despite the day&#8217;s decline, the stock surged 47.7% to $0.92 in after-hours trading due to a&nbsp;<a href="https://in.benzinga.com/general/biotech/25/04/44636945/sangamo-therapeutics-stock-surges-after-the-bell-whats-going-on">new agreement</a> with Eli Lilly, granting a worldwide exclusive license for its proprietary technology.
Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)
Bank of America&#8217;s shares dropped 11.06%, closing at $37.22. The stock&#8217;s intraday high was $38.84, with a low of $37.02, and a 52-week range of $48.08 to $34.15. The bank&#8217;s stock was hit hard by&nbsp;<a href="https://www.benzinga.com/news/25/04/44627173/whats-going-on-with-bank-of-america-bac-shares-15">trade tensions</a>&nbsp;and fears of an economic downturn, which threaten its key revenue drivers.
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock fell 5.47% to $282.76, reaching an intraday high of $284.99 and a low of $251.27. The stock&#8217;s 52-week high and low are $488.54 and $138.80. Despite the overall market decline, Tesla&#8217;s shares fell after the company reported a <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44635878/tesla-shares-are-falling-today-whats-going-on">weaker-than-expected performance</a> for the first quarter, with a decline in vehicle production and deliveries.
Image via Shutterstock
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/44602870/anthony-scaramucci-hates-it-when-trump-pumps-his-own-coin-but-loves-the-presidents-bitcoin" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Hates It When Trump Pumps His Own Coin, But Loves The President&#8217;s Bitcoin Moves — This Complex Crypto Relationship Decoded</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

FIVE

TSLA

RH, Five Below, Sangamo, Bank Of America, Tesla: Why These 5 Stocks Are On Investors' Radars Amid Trump Tariff Meltdown (CORRECTED)

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares increased by 94.6% to $0.9 during Thursday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares moved upwards by 85.35% to $0.81. The market value of their outstanding shares is at $3.8 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares rose 29.54% to $0.81. The market value of their outstanding shares is at $180.9 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares rose 15.19% to $1.63. The market value of their outstanding shares is at $97.0 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares moved upwards by 10.49% to $0.2. The company's market cap stands at $10.4 million. </li>
<li>Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) shares increased by 8.19% to $6.6. The company's market cap stands at $110.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock declined by 36.2% to $0.55 during Thursday's after-market session. The company's market cap stands at $16.9 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 28.95% to $0.47. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares declined by 15.16% to $0.37. The market value of their outstanding shares is at $3.1 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock fell 13.37% to $0.75. The market value of their outstanding shares is at $1.8 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock declined by 9.28% to $5.67. The company's market cap stands at $9.3 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock declined by 7.53% to $5.16. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

ALDX

BBLG

COYA

ERNA

GNPX

PRTG

VRPX

12 Health Care Stocks Moving In Thursday's After-Market Session

Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares are surging in Thursday&#8217;s after-hours session after the company announced a new agreement with <a href="https://www.benzinga.com/pressreleases/25/04/b44635260/sangamo-therapeutics-announces-capsid-license-agreement-with-lilly-to-deliver-genomic-medicines-fo">pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</a>.
What Happened: Sangamo Therapeutics entered into a license agreement with Eli Lilly, granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
Sangamo noted that STAC-BBB has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates.
The genomic medicine company said the license allows Eli Lilly to utilize the STAC-BBB capsid for one initial target. Eli Lilly has the right to add up to four additional targets, but will be required to pay additional license fees.
Sangamo will receive an upfront payment of $18 million and is eligible to earn up to $1.4 billion in additional license fees and milestone payments.
&#8220;We believe STAC-BBB, our industry-leading intravenously delivered AAV capsid, has the potential to play an important role in the treatment landscape by addressing longstanding challenges associated with delivering therapies to the central nervous system,&#8221; said Sandy Macrae, CEO of Sangamo.
&#8220;We are pleased to be sharing STAC-BBB with Lilly to advance potential treatments for neurological diseases with significant unmet medical needs. This marks the third agreement with a pharmaceutical company since we announced the discovery of STAC-BBB in March 2024 and demonstrates the continued industry interest in our capsid delivery technology.&#8221;
Sangamo will be responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly will be responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing and global commercialization of any resulting gene therapy products.
SGMO Price Action: <a href="http://benzinga.com/quote/sgmo">Sangamo shares</a> were up 26.13% after hours, trading at 78 cents at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Sangamo Therapeutics.

Biotech

Health Care

After-Hours Center

Sangamo Therapeutics Stock Surges After The Bell: What's Going On?

WIIM

Sangamo Therapeutics shares are trading higher after the company announced it entered a capsid license agreement with Lilly.

Sangamo Therapeutics Enters Capsid License Agreement With Lilly; To Receive $18M Upfront License Fee And Is Eligible To Earn Up To $1.4B In Additional Licensed Target Fees And Milestone Payments

Across the recent three months, 8 analysts have shared their insights on Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target of $6.5, a high estimate of $10.00, and a low estimate of $2.00. Experiencing a 11.92% decline, the current average is now lower than the previous average price target of $7.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1742328055_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Sangamo Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jim Birchenough</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sangamo Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sangamo Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SGMO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sangamo Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Sangamo Therapeutics: A Closer Look</h2>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Key Indicators: Sangamo Therapeutics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sangamo Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 425.77%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.99%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sangamo Therapeutics's ROE excels beyond industry benchmarks, reaching 29.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sangamo Therapeutics's ROA excels beyond industry benchmarks, reaching 9.19%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.71, Sangamo Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Assess Sangamo Therapeutics: What You Need To Know

RBC Capital analyst Luca Issi reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Sector Perform and maintains $2 price target.

Price Target

Reiteration

RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target

U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.
On Monday, stocks continued their recovery from last week&#8217;s sell-off, which had pushed the S&amp;P 500 into correction territory amid growing concerns over the U.S. economy&#8217;s ability to withstand President Donald Trump&#8216;s trade war.
The two-day meeting of the Federal Open Market Committee will begin today as they discuss and announce their decision on interest rates slated to be released tomorrow. Chairman Jerome Powell will address a press conference on Wednesday afternoon.
The 10-year Treasury yield stood at 4.31%, while the two-year yield was at 4.04%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 99% chance that the Federal Reserve will keep interest rates unchanged tomorrow.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.21%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped slightly in premarket on Monday. The SPY was down 0.15% to $566.37, and the QQQ also declined 0.25% to $481.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Real estate, energy, and consumer staples stocks led Monday&#8217;s market rally, with significant gains across the S&amp;P 500. Conversely, consumer discretionary stocks dipped.
This sector-driven strength propelled the Dow Jones higher extending the market&#8217;s recovery after last week&#8217;s sharp declines, which saw the Dow lose 3.1% and the S&amp;P 500 drop over 2%.
In company news, Guess? Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares surged 30% on acquisition interest, and Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares climbed 9% following the launch of new AI models.
Economic data presented a mixed picture, with retail sales growth below expectations, a sharp drop in the NY Empire State Manufacturing Index, and a decline in housing market confidence.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.31%</td>
<td>17,808.66</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.64%</td>
<td>5,675.12</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.85%</td>
<td>41,841.63</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.19%</td>
<td>2,068.33</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The market sentiment seemed to be recovering on Monday after the S&amp;P 500 index recorded an upmove in 90% of its issues for two consecutive days. Ryan Detrick of Carson Research highlighted that this was a rare occurrence when 90% of S&amp;P 500 constituents rose back-to-back for two days.
According to the historical data shared by him, this has only happened 12 times since 1972 and the index has been higher in all instances after a year.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Back-to-back 90% advancing issues for the S&amp;P 500. Using <a href="https://twitter.com/NDR_Research?ref_src=twsrc%5Etfw">@NDR_Research</a> data back to 1972 shows higher six and 12 months later every single time, with much better than average returns. I&#39;m sure this will make everyone mad, but it made me &#x1f603; <a href="https://t.co/QWf8lJx2eQ">pic.twitter.com/QWf8lJx2eQ</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1901824344839336317?ref_src=twsrc%5Etfw">March 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Liz Ann Sonders and Kevin Gordon of Charles Schwab said in a note "The only thing we can be certain of is that things will remain uncertain for the time being."
They quoted the data from a few years ago when confidence metrics went through a soft patch giving a &#8220;false&#8221; recessionary signal amid strong underlying growth and the hard data. They termed it as a &#8220;vibecession.&#8221;
Whereas they termed the current period as &#8220;vibespansion," which was evident a few months ago, however, many strong sentiment metrics are receding. "If the soft data stay soft long enough, we see more risk of the hard data catching down," the note added.
Edward Yardeni or Yardeni Research highlighted that the markets could have bottomed out on Thursday last week and rose on Friday and Monday because there was no comment from Trump on tariffs.
He said, "From a sentiment perspective, it is possible that Thursday's selloff followed by Friday's rally marked a bottom in the correction. We will be more inclined to call a bottom when we see the stock market move higher on a day or days when Trump blusters about tariffs again, which he did not do on Friday."
"Any day without a Trump tariff comment is a good day for the market. We know that on April 2 there will be lots of reciprocal tariffs imposed on many more nations by the administration, undoubtedly eliciting lots of comments from Tariff Man," he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>February&#8217;s housing starts, building permits, and import price index data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Also, February&#8217;s industrial production and capacity utilization data will be released at 9:15 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) was up 0.77% in premarket on Tuesday ahead of its earnings before the opening bell. Analysts expect earnings of 4 cents per share on revenue of $424.00 million.</li>
</ul>
<ul>
<li>HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) advanced 0.28% as Wall Street expects it to report earnings of 72 cents per share on revenue of $306.05 million after the closing bell.</li>
</ul>
<ul>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STN#NASDAQ">STN</a>) rose 0.49% ahead of its earnings after the closing bell. Analysts expect earnings of 35 cents per share on revenue of $647.56 million.</li>
</ul>
<ul>
<li>Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) jumped 2.33% after posting an upbeat earnings result for its fourth quarter on Monday.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) dropped 6.83% after reporting worse-than-expected fourth-quarter financial results.</li>
</ul>
<ul>
<li>Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) was 4.39% higher continuing the momentum from yesterday following the launch of new AI models.</li>
</ul>
<ul>
<li>Bon Natural Life Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) surged 29.71% after it secured $12 million in gross proceeds from a best efforts unit offering.</li>
</ul>
<ul>
<li>Harrow Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) zoomed 24.14% after it projected 2025 revenue of over $280 million, driven by branded products.</li>
</ul>
<ul>
<li>Bakkt Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) plunged 30.24% after it rescheduled its fourth-quarter earnings call to March 18, 2025.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.35% to hover around $68.28 per barrel.
The gold spot index was up by 0.70% to $3,022.11 per ounce. Its last record high was at $3,028.49 per ounce. The Dollar Index was down by 0.05% at the 103.322 level.
Asian markets closed higher on Tuesday with China&#8217;s CSI 300, Japan's Nikkei 225, South Korea's Kospi, Australia's ASX 200, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex advancing in trade. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44371661/ai-bubble-bursting-magnificent-7s-profit-margins-face-pressure-as-capital-spending-can-tumble-in">AI Bubble Bursting? Magnificent 7&#8217;s Profit Margins Face Pressure As &#8216;Capital Spending Can Tumble&#8217; In 2025</a></li>
</ul>
Photo courtesy: Shutterstock

BIDU

Bakkt Holdings, Inc. Class A Common Stock

BKKT

GETY

HROW

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) to report quarterly earnings at 4 cents per share on revenue of $424.00 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. IHS shares gained 0.5% to $3.93 in after-hours trading.</li>
<li>Analysts are expecting HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) to post quarterly earnings at 72 cents per share on revenue of $306.05 million. The company will release earnings after the markets close. HealthEquity shares rose 1.1% to $101.87 in after-hours trading.</li>
<li>Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) posted upbeat results for its fourth quarter on Monday. Getty Images shares fell 0.9% to $2.1301 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported worse-than-expected fourth-quarter financial results. Sangamo Therapeutics shares fell 3% to $0.98 in the after-hours trading session.</li>
<li>Analysts expect StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) to post quarterly earnings at 35 cents per share on revenue of $647.56 million after the closing bell. StoneCo shares rose 0.1% to $10.20 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo courtesy: Shutterstock

STNE

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Guidance

Sangamo Therapeutics Expects FY25 Operating Expenses On A Non-GAAP Basis Are To Be Roughly In Line With 2024

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 67.65 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $7.551 which missed the analyst consensus estimate of $13.617 million by 100.00 percent. This is a 100.00 percent decrease over sales of $2.042 million the same period last year.

Earnings Misses

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $1.68 per share on revenue of $597.66 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is likely to report earnings for its fourth quarter. 
• CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $50.11 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $20.21 million. 
• NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) is projected to report earnings for its fourth quarter. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is projected to report quarterly earnings at $2.07 per share on revenue of $1.81 billion. 
• Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $81.72 million. 
• Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter. 
• Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.74 million. 
• Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is likely to report earnings for its fourth quarter. 
• Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $116.41 million. 
<h3>Companies Reporting After The Bell</h3>
• DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) is likely to report earnings for its fourth quarter. 
• Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) is expected to report earnings for its fourth quarter. 
• High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report earnings for its first quarter. 
• Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is expected to report earnings for its fourth quarter. 
• Health In Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>) is estimated to report earnings for its first quarter. 
• Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is expected to report quarterly loss at $0.11 per share on revenue of $42.51 million. 
• Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $40.84 million. 
• Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $3.77 million. 
• FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its fourth quarter. 
• FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.20 per share on revenue of $24.91 million. 
• Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is likely to report earnings for its fourth quarter. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report quarterly loss at $1.25 per share on revenue of $21.61 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is estimated to report earnings for its fourth quarter. 
• Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $33.60 million. 
• RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) is expected to report earnings for its first quarter. 
• Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $59.09 million. 
• Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is likely to report quarterly loss at $0.05 per share on revenue of $102.46 million. 
• Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $46.55 million. 
• Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $244.87 million. 
• Lithium Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $48.40 million. 
• Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is projected to report quarterly loss at $0.22 per share on revenue of $35.55 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPS

BLTE

CBAT

CODA

CWCO

DMAC

FGEN

FINV

HITI

HNRG

HYPR

INSE

KODK

LNZA

LPRO

NRGV

NRXP

NXPL

QFIN

QTRX

RBOT

RFIL

RILY

SAIC

SNDA

Earnings Scheduled For March 17, 2025

According to multiple media reports on Thursday, Pfizer&nbsp;Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez.
In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years" rel="noreferrer noopener">uniQure/ CSL Behring&#8217;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years</a>
In a statement to&nbsp;Nikkei Asia, Pfizer <a target="_blank" href="https://asia.nikkei.com/Business/Pharmaceuticals/Pfizer-halts-work-on-hemophilia-gene-therapy" rel="noreferrer noopener">said</a> the decision was due to "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.&#8221;
The U.S. drugmaker said it would focus on different treatment for the disorder, citing low interest.
In December 2024, Pfizer walked away&nbsp;from its hemophilia A co-development pact with Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) giroctocogene fitelparvovec, an investigational gene <a target="_blank" href="https://www.benzinga.com/24/12/42740738/sangamo-therapeutics-stock-plunges-as-pfizer-terminates-hemophilia-gene-therapy-pact" rel="noreferrer noopener">therapy product candidate</a>.
According to a Reuters report, Pfizer will continue to invest resources in Hympavzi (marstacimab-hncq), which is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A or hemophilia B.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">auto-injector pen</a>.
Earlier this month, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">with and without inhibitors</a>.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta&nbsp;(voxelotor) for sickle cell disease (SCD) in all markets&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41035514/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worl" rel="noreferrer noopener">where it is approved</a>.
Pfizer's decision is based on the totality of clinical data indicating that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048780/pfizer-voluntarily-withdraws-sickle-cell-disease-treatment-oxbryta-from-global-market-due-to-pain" rel="noreferrer noopener">cell patient population</a>.
Price Action: PFE stock is up 0.87% at $26.13 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43885302/apple-expands-apple-tv-to-android-eyes-subscription-growth-and-ecosystem-expansion-analyst-says" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>

Large Cap

General

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Sangamo Therapeutics To Present Updated Phase 1/2 STAAR Study Data In Fabry Disease Showing Sustained Benefit, Improvements In Kidney Function And Favorable Safety Profile

In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing the previous average price target of $7.73, the current average has increased by 4.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1737982851_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Sangamo Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jim Birchenough</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sangamo Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sangamo Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Sangamo Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SGMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sangamo Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Sangamo Therapeutics's Background</h2>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Understanding the Numbers: Sangamo Therapeutics's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Sangamo Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 425.77%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sangamo Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sangamo Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.71, Sangamo Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts

Penny Stocks

Press Releases

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Comments

Sangamo Therapeutics

ニュース

最新ニュース Sangamo Therapeutics (NASDAQ:SGMO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル